BioFocus | News & events | Offering a comprehensive suite of discovery products and services

Galapagos and Cystic Fibrosis Foundation Therapeutics announce new drug discovery collaboration worth up to $8.1 million U.S. dollars

Thu 29 Nov 2007

Galapagos NV (Euronext & LSE: GLPG) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the non-profit affiliate of the Cystic Fibrosis Foundation, announced today a new collaboration aimed at discovering new treatments for cystic fibrosis.
BioFocus DPI launches GPCR SARfari

Thu 11 Oct 2007

BioFocus DPI, a Galapagos Company, is launching a new version of the GPCR SARfari discovery tool at the American Chemical Society meeting this week in San Diego (USA).
BioFocus DPI enhances ADME optimization capabilities

Tue 09 Oct 2007

##Summary##
BioFocus DPI launches five new compound libraries

Tue 04 Sep 2007

Five novel hit-finding compound libraries targeting the ion channel gene family have been released today by BioFocus DPI. Created using advanced modeling tools, these new libraries are specifically aimed at voltage-dependent and ligand-gated channels, two of the most important and commonly chosen classes of ion channels for drug discovery.
Galapagos announces expanded relationship with AstraZeneca: BioFocus DPI to provide drug discovery services to US-site

Wed 08 Aug 2007

Galapagos NV (Euronext & LSE: GLPG) announced today that its service division, BioFocus DPI, has entered into a new drug discovery collaboration with AstraZeneca (LSE, NYSE, OMX: AZN), a global pharmaceutical leader.
Galapagos announces milestone in collaboration with Boehringer Ingelheim

Fri 20 Jul 2007

Galapagos NV (Euronext & LSE: GLPG) announced today that its BioFocus DPI service division has received a milestone payment in the autoimmune discovery research collaboration with Boehringer Ingelheim.
BioFocus DPI launches Kinase SARfari knowledge base

Wed 11 Jul 2007

BioFocus DPI, a Galapagos company, is launching its latest knowledge base, Kinase SARfari at this week’s World Pharmaceutical Congress. This fully integrated data repository and research workbench focuses on the protein kinase family of drug targets.
Galapagos announces new collaboration agreements and a management appointment

Mon 21 May 2007

Galapagos NV (Euronext & LSE: GLPG) announces that its service division BioFocus DPI has signed agreements with Cancer Research Technology Limited (CRT) and the University of Rochester Medical Center (URMC).
Galapagos and AstraZeneca enter new drug discovery collaboration

Thu 19 Apr 2007

Galapagos NV (Euronext & LSE: GLPG) announced today that its service division, BioFocus DPI, has entered into a new drug discovery collaboration with AstraZeneca (LSE, NYSE, OMX: AZN), a global pharmaceutical leader.
Galapagos announces agreement worth up to €6.3 million with United States Environmental Protection Agency (EPA)

Wed 18 Apr 2007

Galapagos NV (Euronext & LSE: GLPG) announces today that its service division BioFocus DPI has entered into a multi year compound management agreement with the United States EPA. BioFocus DPI will provide chemical procurement and compound management services as part of the EPA’s ToxCast™ Program (Prioritization of Environmentally Relevant Chemicals).
Galapagos signs two new drug discovery collaborations with Ono Pharmaceutical

Mon 16 Apr 2007

Galapagos NV (Euronext & LSE: GLPG) announced today that its BioFocus DPI service division has signed two new collaborations with Ono Pharmaceutical Company Ltd. (Tokyo: OSA). These collaborations build on the successful relationship between Ono and DPI, which began in 2004.
Galapagos to supply chemical compound sets to Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica NV

Thu 08 Mar 2007

Galapagos NV (Euronext & LSE: GLPG) announced today that its service division, BioFocus DPI, has entered into an agreement to supply small molecule compounds for drug discovery to the Johnson & Johnson Pharmaceutical Research & Development Division of Janssen Pharmaceutica NV (J&JPRD).
Galapagos and the University of Bristol enter drug discovery collaboration

Thu 15 Feb 2007

Mechelen, Belgium and Bristol, United Kingdom; 15 February 2007 – Galapagos NV (Euronext & LSE: GLPG) and the University of Bristol today announced a new drug discovery collaboration in the field of cancer research. Galapagos’ service division BioFocus DPI will provide lead optimization services for a University of Bristol research program focusing on destroying cancer cells.
Galapagos expands and extends drug discovery collaboration with Amgen into 2008

Wed 03 Jan 2007

Galapagos NV (Euronext & LSE: GLPG) announced that its service division BioFocus DPI has expanded and extended its longstanding drug discovery collaboration with Amgen through 2007 and 2008. BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply biologically-directed library compounds to Amgen’s discovery programs.

Protein Kinase 2010: Signalling Success

Registration to this event is FREE

In this section

News & events

Galapagos and Cystic Fibrosis Foundation Therapeutics announce new drug discovery collaboration worth up to $8.1 million U.S. dollars

BioFocus DPI launches GPCR SARfari

BioFocus DPI enhances ADME optimization capabilities

BioFocus DPI launches five new compound libraries

Galapagos announces expanded relationship with AstraZeneca: BioFocus DPI to provide drug discovery services to US-site

Galapagos announces milestone in collaboration with Boehringer Ingelheim

BioFocus DPI launches Kinase SARfari knowledge base

Galapagos announces new collaboration agreements and a management appointment

Galapagos and AstraZeneca enter new drug discovery collaboration

Galapagos announces agreement worth up to €6.3 million with United States Environmental Protection Agency (EPA)

Galapagos signs two new drug discovery collaborations with Ono Pharmaceutical

Galapagos to supply chemical compound sets to Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica NV

Galapagos and the University of Bristol enter drug discovery collaboration

Galapagos expands and extends drug discovery collaboration with Amgen into 2008

Send to a friend

Related links

Get in contact with us

Where to find us